Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R, Descamps G, Bellanger C, Dousset C, Maïga S, Alberge JB, Derrien J, Cruard J, Minvielle S, Lilli NL, Godon C, Le Bris Y, Tessoulin B, Amiot M, Gomez-Bougie P, Touzeau C, Moreau P, Chiron D, Moreau-Aubry A, Pellat-Deceunynck C. Durand R, et al. Among authors: touzeau c. Blood. 2024 Mar 28;143(13):1242-1258. doi: 10.1182/blood.2023021581. Blood. 2024. PMID: 38096363
Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.
Cahu X, Rialland F, Touzeau C, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Cahu X, et al. Among authors: touzeau c. Biol Blood Marrow Transplant. 2009 Dec;15(12):1531-7. doi: 10.1016/j.bbmt.2009.07.021. Epub 2009 Sep 25. Biol Blood Marrow Transplant. 2009. PMID: 19896076 Free article.
ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M. Bodet L, et al. Among authors: touzeau c. Blood. 2011 Oct 6;118(14):3901-10. doi: 10.1182/blood-2010-11-317438. Epub 2011 Aug 11. Blood. 2011. PMID: 21835956 Free article.
Cereblon expression in multiple myeloma: not ready for prime time.
Lodé L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F, Minvielle S, Pellat-Deceunynck C, Bene MC, Moreau P. Lodé L, et al. Among authors: touzeau c. Br J Haematol. 2013 Oct;163(2):282-4. doi: 10.1111/bjh.12478. Epub 2013 Jul 17. Br J Haematol. 2013. PMID: 23862718 Free article. No abstract available.
Elotuzumab for the treatment of multiple myeloma.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Future Oncol. 2014 May;10(6):949-56. doi: 10.2217/fon.14.56. Future Oncol. 2014. PMID: 24941981 Review.
New data on subcutaneous bortezomib.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Acta Haematol. 2015;133(1):26-8. doi: 10.1159/000362639. Epub 2014 Jul 1. Acta Haematol. 2015. PMID: 24993571 No abstract available.
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.
Moreau P, Kolb B, Attal M, Caillot D, Benboubker L, Tiab M, Touzeau C, Leleu X, Roussel M, Chaleteix C, Planche L, Chiffoleau A, Fortin J, Avet-Loiseau H, Mary JY, Hulin C, Facon T. Moreau P, et al. Among authors: touzeau c. Blood. 2015 May 14;125(20):3100-4. doi: 10.1182/blood-2015-02-626168. Epub 2015 Mar 17. Blood. 2015. PMID: 25784682 Free article. Clinical Trial.
173 results